Trial Profile
Efficacy of memantine in patients with moderate-to-severe Alzheimer's disease: results of pooled analysis, using realistic definitions of response, of two randomized, double-blind, placebo-controlled trials in Japan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 15 Aug 2017 Status changed from not yet recruiting to completed.
- 15 Feb 2017 New trial record